Inventor · disambiguated record
Hassan Javanbakht
Also filed as: JAVANBAKHT HASSAN
9 granted patents·10 pending applications·39 citations·filing 2012–2024
86Inventor score
Files withHOFFMANN LA ROCHE10BLUEJAY THERAPEUTICS INC4GILEAD SCIENCES INC2JAVANBAKHT HASSAN1RIBOSCIENCE LLC1
Top patents by PatentIndex Score
19 records- 0194US9458153B2Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2015·Granted Oct 4, 2016·23 cites·20 claims
- 0289US10829555B2Oligonucleotides for reduction of PD-L1 expressionHOFFMANN LA ROCHE·Filed 2020·Granted Nov 10, 2020·3 cites·14 claims
- 0387US11191775B2PAPD5 and PAPD7 inhibitors for treating a hepatitis B infectionHOFFMANN LA ROCHE·Filed 2017·Granted Dec 7, 2021·2 cites·8 claims
- 0487US10745480B2Oligonucleotides for reduction of PD-L1 expressionHOFFMANN LA ROCHE·Filed 2019·Granted Aug 18, 2020·3 cites·30 claims
- 0586US11466081B2Oligonucleotides for reduction of PD-L1 expressionHOFFMANN LA ROCHE·Filed 2020·Granted Oct 11, 2022·2 cites·22 claims
- 0685US11534452B2Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infectionHOFFMANN LA ROCHE·Filed 2017·Granted Dec 27, 2022·2 cites·18 claims
- 0783US9949966B2Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2016·Granted Apr 24, 2018·4 cites·21 claims
- 0882US12281307B2Oligomers and oligomer conjugatesHOFFMANN LA ROCHE·Filed 2023·Granted Apr 22, 2025·0 cites·1 claims
- 0977US2023210887A1Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infectionHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1073US2022096527A1Papd5 and papd7 inhibitors for treating a hepatitis b infectionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1168US2024269235A1INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USEGILEAD SCIENCES INC·Filed 2023·Application pending·0 cites
- 1267US2025026745A117-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereofBLUEJAY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1366US11896648B2Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereofGILEAD SCIENCES INC·Filed 2021·Granted Feb 13, 2024·0 cites·14 claims
- 1466US2024182472A1Indazole pyridone compounds and uses thereofBLUEJAY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1564US2025009899A1Fusion proteins containing il21 muteins for treating cancer and viral diseasesBLUEJAY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1663US2024400650A1Anti-HBsAg antibody for treatment of chronic hepatitis DBLUEJAY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1755US2017283496A1Oligonucleotides for reduction of pd-l1 expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Application pending·0 cites
- 1847US2013018011A1Method of treating dengue feverJAVANBAKHT HASSAN·Filed 2012·Application pending·0 cites
- 1941US2016168186A1Method of Treating Dengue FeverRIBOSCIENCE LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hassan Javanbakht files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →